Articles Tagged With: lipids
-
Cardiovascular Outcomes with Bempedoic Acid, a New Statin Alternative
A trial of bempedoic acid vs. placebo for statin-intolerant patients showed bempedoic acid significantly lowered LDL cholesterol levels and prevented more major adverse cardiovascular events after a median follow-up of 41 months. Although nonserious side effects were numerically higher for those on bempedoic acid, serious adverse events were not significantly different from placebo.
-
An Oral PCSK9 Inhibitor — Coming Soon?
A Phase IIb study of four doses of MK-0616, an orally administered PCSK9 inhibitor, compared to placebo showed significant reductions in LDL cholesterol levels without any differences in adverse effects over eight weeks.
-
Effectiveness of Dietary Supplements on Lipid and Inflammatory Biomarkers
In a comparison of rosuvastatin 5 mg/day, six common dietary supplements marketed for improving heart health, and placebo, none reduced high-sensitivity C-reactive protein levels. Only rosuvastatin significantly reduced LDL cholesterol levels compared to placebo.
-
Improving Statin Tolerance in Elderly Patients
In a post-hoc analysis of the RACING trial, researchers found the combination of moderate-intensity statin and ezetimibe therapy vs. high-intensity statin therapy alone in older subjects resulted in similar reductions in cardiovascular events over three years, but fewer adverse effects with the combination therapy.
-
The Best Use of Statins in Patients with Coronary Artery Disease
A randomized, multicenter study of high-intensity statin therapy to a treat-to-target approach in coronary artery disease patients showed no difference in three-year outcomes. These results suggest treating to a target may be more suitable to individual patients compared to blanket high-intensity statin use.
-
Effectiveness of Dietary Supplements on Lipid and Inflammatory Biomarkers
In a comparison of rosuvastatin 5 mg/day, six common dietary supplements marketed for improving heart health, and placebo, none reduced high-sensitivity C-reactive protein levels. Only rosuvastatin significantly reduced LDL cholesterol levels compared to placebo.
-
Long-Term Statin Use Associated with Lower Stroke Risk
A cohort of Danish patients who were taking the cholesterol control medication were less likely to experience an intracerebral hemorrhage.
-
Triglyceride-Lowering Therapy and Cardiovascular Events
Researchers studied pemafibrate vs. placebo in patients with type 2 diabetes, mild-to-moderate triglyceride elevations, and low levels of HDL and well-controlled LDL cholesterol. Despite a 31% reduction in triglyceride levels, there was no improvement in the risk of cardiovascular outcomes over a median follow-up of 3.4 years.
-
Statins Plus Ezetimibe vs. Statins Alone
A comparison of rosuvastatin 10 mg/day plus ezetimibe (10 mg/day) to 20 mg/day of rosuvastatin alone showed non-inferiority in three-year major cardiovascular outcomes, with lower LDL cholesterol levels and fewer episodes of drug discontinuation or dose reductions in the combination therapy group.
-
Men More Likely to Produce High-Risk, Dangerous Carotid Artery Plaques
Investigators found significant differences in mean total plaque volume between men and women. Men were more likely to experience intraplaque hemorrhage and produce lipid-rich necrotic cores with coexistence of calcifications. Men also were more likely to exhibit thin or ruptured fibrous caps or ulcerations in their atherosclerotic plaques.